TREATMENT |
ACT GENOMICS

Transforming cancer care for all

ACT Genomics is an internationally-recognized award-winning cancer solution provider. Combining our expertise in the fields of cancer genomics and bioinformatics with our cutting-edge technologies, we are able to assist medical practitioners and scientists with genomics-driven recommendations and data for cancer treatment strategy and discovery.

Turning Genomics
Into Action

ACT Genomics is a leading genomics diagnostics and research company specializing in precision medicine for cancer patients. Our technology empower clinicians and patients to make informed decisions about cancer treatment options.
Learn more

ACT Genomics is a world-leading molecular insights company that is making precision medicine a reality for thousands.

Treatment Selection
Disease Monitoring
Risk Prediction

About ACT Genomics

Comprehensive genomic profiling for personalised cancer treatment
The ability to perform a comprehensive genomic profiling test on an individual tumor helps open the door for personalized medicine, and a future where a person is matched with a treatment that targets the specific weaknesses in his or her cancer.
Actionable Cancer Solutions
We aim to reimagine and positively impact cancer management by using both our knowledge of cancer genomics and advanced technology capabilities. We partner with physicians to facilitate the best personalised treatment decisions for patients.
The First Asia-Based Company to Receive FDA Clearance
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Comprehensive genomic profiling for personalised cancer treatment
Actionable Cancer Solutions
The First Asia-Based Company to Receive FDA Clearance

Patients’ Stories

Neuroendocrine Tumor Patient: Ms. Chen
Learning to face death teaches you how to truly live.
Liver Cancer Survivor: Dr. Andrew Tay
Unexpectedly diagnosed with hepatocellular carcinoma during his work trip, Dr. Andrew successfully underwent life-threatening surgery.
Ovarian Cancer Patient: Ms. Chang
While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery.
Stage 4 Lung Cancer Survivor: Mr. Yu
Mr. Yu wasn't a good candidate for targeted therapies owing to his negative results from the usual lung cancer biomarkers testing.

Transforming cancer care for all

Learn more
Prenetics
PreventionEarly DetectionTreatment
Investor Relations
Company
About UsCareersResourcesPressContact Us
© 2024 Prenetics Global Limited | All rights reserved